Bragar Eagel & Squire announces ADMA class action with Aug. 10, 2026 lead plaintiff deadline

Multiple plaintiff law firms are now soliciting investors in the securities class action against ADMA Biologics, Inc. pending in the U.S. District Court for the District of New Jersey, where investors have until August 10, 2026 to seek appointment as lead plaintiff. The complaint, captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918, alleges ADMA made false or misleading statements and omitted material facts about its business, including alleged channel stuffing, an undisclosed related-party distributor or transaction, and weak internal controls during the August 9, 2024 to March 25, 2026 class period. Bleichmar Fonti & Auld LLP said the suit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and centers on allegations that ADMA's reported 20% growth in 2025 was driven by a de facto channel stuffing scheme despite waning demand for its flagship product, ASCENIV. The filing points to a March 24, 2026 report by Culper Research alleging that, absent the practice, ADMA would have posted a 3% revenue decline in 2025 rather than the reported 20% growth. ADMA shares fell $2.26, or 16.6%, to $11.33 on March 24, 2026, then dropped another $1.70, or 15%, to $9.63 on March 25, and later fell $1.34, or 13.9%, to $8.29 on March 29 after Investing.com reported on March 26 that Cantor had downgraded the stock over concerns raised by the short report.